Filing Details

Accession Number:
0001209191-18-015882
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-03-02 17:34:50
Reporting Period:
2018-02-28
Accepted Time:
2018-03-02 17:34:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1347178 Vanda Pharmaceuticals Inc. VNDA Pharmaceutical Preparations (2834) 030491827
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1506314 Patrick James Kelly 2200 Pennsylvania Avenue
Suite 300E
Washington DC 20037
Evp & Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-02-28 40,000 $0.00 208,066 No 4 A Direct
Common Stock Disposition 2018-03-01 8,532 $18.72 199,534 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Acquisiton 2018-02-28 80,000 $0.00 80,000 $18.85
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
80,000 2028-02-27 No 4 A Direct
Footnotes
  1. Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments beginning February 28, 2019, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
  2. Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs as reflected in this Form 4. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.
  3. The price reported in Column 4 is a weighted average price. The Reporting The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.35 to $18.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
  4. The option vests in forty-eight (48) equal monthly installments beginning on February 28, 2018, provided the Reporting Person remains continuously employed by the Issuer through each vesting date.